Leerink Partnrs Expects Reduced Earnings for Exact Sciences

Exact Sciences Co. (NASDAQ:EXAS) – Investment analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for Exact Sciences in a research note issued to investors on Monday, April 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn ($0.14) per share for the quarter, down from their previous forecast of ($0.06). The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q2 2025 earnings at ($0.01) EPS and FY2025 earnings at $0.20 EPS.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The business had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million.

Several other brokerages have also recently weighed in on EXAS. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Bank of America cut their target price on Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Mizuho initiated coverage on Exact Sciences in a research report on Thursday, April 10th. They set an “outperform” rating and a $60.00 price target for the company. Barclays cut their price objective on Exact Sciences from $65.00 to $55.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Finally, Royal Bank of Canada assumed coverage on Exact Sciences in a report on Thursday, March 13th. They set a “sector perform” rating and a $52.00 target price for the company. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $69.25.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $44.09 on Wednesday. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. Exact Sciences has a fifty-two week low of $39.97 and a fifty-two week high of $72.83. The firm has a market cap of $8.19 billion, a PE ratio of -7.92 and a beta of 1.14. The business has a 50 day moving average price of $45.50 and a 200-day moving average price of $54.54.

Institutional Trading of Exact Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of EXAS. Capital World Investors grew its holdings in shares of Exact Sciences by 10.7% during the fourth quarter. Capital World Investors now owns 17,537,617 shares of the medical research company’s stock valued at $985,439,000 after buying an additional 1,696,321 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Exact Sciences by 74.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company’s stock valued at $323,669,000 after purchasing an additional 2,462,165 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Exact Sciences by 25.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company’s stock worth $239,922,000 after purchasing an additional 876,985 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Exact Sciences by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 3,122,798 shares of the medical research company’s stock worth $175,165,000 after purchasing an additional 16,828 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its holdings in shares of Exact Sciences by 107.7% during the fourth quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company’s stock valued at $164,037,000 after purchasing an additional 1,513,873 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.